| Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method S Tezcan, FV Izzettin, M Sancar, PF Yumuk, S Turhal Pharmacology & Pharmacy 4 (03), 296, 2013 | 28 | 2013 |
| Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer S Tezcan, FV İzzettin, M Sancar, NS Turhal, PF Yumuk European Journal of Hospital Pharmacy, 2017 | 27 | 2017 |
| High performance liquid chromatographic determination of free cisplatin in different cancer types S Tezcan, F Özdemir, S Turhal, FV İzzettin Der Pharma Chemica 5 (5), 169-174, 2013 | 18 | 2013 |
| Aprepitant in the treatment of subacute sclerosing panencephalitis: a randomized, double-blind, placebo-controlled study I Oncel, M Sancar, B Konuskan, F Arioz, S Tezcan, E Arman-Kandirmaz, ... Pediatric Neurology, 2020 | 8 | 2020 |
| The role of the clinical pharmacist in patient education and monitoring of patients under warfarin treatment FV İzzettin, S Çelik, RD Acar, S Tezcan, N Aksoy, MY Bektay, M Sancar | 7 | 2019 |
| Community Pharmacists’ Knowledge on Cancer and Screening Methods A Uygun, ND Caliskan, S Tezcan Journal of Oncology Pharmacy Practice 29 (2), 386-392, 2023 | 4 | 2023 |
| Assessment of chemotherapy-related educational needs of colorectal cancer patients S Tezcan, GI Tanir, H Yilmaz, S Memis, Y Sahin, PF Yumuk, ... INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 40 (1), 289-289, 2018 | 3* | 2018 |
| Kolon Kanseri Hastalarında Farmasötik Bakım Gerksinimlerinin Belirlenmesi. MÜ Sağlık Bilimleri Enstitüsü S Tezcan Doktora Tezi, 2016, İstanbul (Danışman: Prof. Dr. Fikret Vehbi Izzettin, 0 | 2 | |
| Pharmacists: current challenges and perspectives LL Villadsen EBSCO eBooks, 2020 | 1 | 2020 |
| Efforts to Validate the Applicability of Established Chemotherapy Treatment in Turkish Cancer Patients NS Turhal, F Dane, S Butur, M Kocak, F Telli Pharm Anal Acta S 14, 2, 2011 | 1 | 2011 |
| Are there any potential drug-drug interactions with oral inhaler medications?: A retrospective study S Tezcan, N Yaban Exploratory Research in Clinical and Social Pharmacy, 100468, 2024 | | 2024 |
| Clinical pharmacy services in cancer patients with hypertension S Tezcan, FN Yılmaz Oncologie, 2024 | | 2024 |
| British Oncology Pharmacy Association Delphi consensus guidelines: Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments S TEZCAN | | 2024 |
| British Oncology Pharmacy Association Delphi consensus guidelines: Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments. et al. Polwart C, Root T, Tezcan S Journal of Oncology Pharmacy Practice, 2024 | | 2024 |
| British Oncology Pharmacy Association Delphi Consensus Guidelines: co-infusion of trometamol-containing calcium folinate (leucovorin) with Systemic Anti-Cancer Treatments C Polwart, T Root, S Tezcan, S Meehan, B Wetherill, C Waterson, ... medRxiv, 2024.02. 10.24302100, 2024 | | 2024 |
| Knowledge, awareness, and attitudes of pharmacists about dermocosmetic products-adescriptive study S TEZCAN | | 2023 |
| Plasma ca125 levels and acute coronary syndrome: Is there a relationship withprognosis S TEZCAN, Ş RABUŞ | | 2023 |
| The effect of clinical pharmacy services in patients with acute coronary syndrome: A randomized controlled study S TEZCAN, Ş APİKOĞLU | | 2023 |
| Therapeutic drug monitoring of aprepitant with liquid chromatography–massspectrometry S TEZCAN, E ARMAN KANDIRMAZ, M SANCAR | | 2023 |
| Evaluation of medication adherence and treatmentsatisfaction İn patients using direct-acting oral anticoagulants S TEZCAN | | 2023 |
